| 000 | 01699 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515203145.0 | ||
| 264 | 0 | _c20100416 | |
| 008 | 201004s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1038/clpt.2009.223 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCavallari, L H | |
| 245 | 0 | 0 |
_aGenetic and clinical predictors of warfarin dose requirements in African Americans. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cApr 2010 |
||
| 300 |
_a459-64 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBlack or African American _xgenetics |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 | _aAlleles |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aApolipoproteins E _xgenetics |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C9 |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMixed Function Oxygenases _xgenetics |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aVitamin K Epoxide Reductases |
| 650 | 0 | 4 |
_aWarfarin _xadministration & dosage |
| 700 | 1 | _aLangaee, T Y | |
| 700 | 1 | _aMomary, K M | |
| 700 | 1 | _aShapiro, N L | |
| 700 | 1 | _aNutescu, E A | |
| 700 | 1 | _aCoty, W A | |
| 700 | 1 | _aViana, M A G | |
| 700 | 1 | _aPatel, S R | |
| 700 | 1 | _aJohnson, J A | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 87 _gno. 4 _gp. 459-64 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/clpt.2009.223 _zAvailable from publisher's website |
| 999 |
_c19450149 _d19450149 |
||